109 research outputs found
Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study
A randomized, double-blind, placebo-controlled, cross-over, dose-escalating, single-center study was conducted to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple once-daily (qd) subcutaneous (sc) doses of pasireotide in healthy male subjects. Subjects received pasireotide 50, 200, or 600μgscqd for 14days and placebo in separate sequences. Thirty-three subjects were randomized. The most frequently reported drug-related adverse events were injection-site reactions (n=18), diarrhea (n=14) and nausea (n=10), which were mostly mild or moderate in intensity. Pasireotide 600μgsc was associated with pre- and post-prandial elevations in glucose levels relative to placebo; however, this effect was less pronounced on day 14 compared with day 1. PK steady state appeared to be achieved after 3days of dosing and PK exposures had a moderate accumulation of 20-40% across doses. Pasireotide demonstrated fast absorption (T max,ss: 0.25-0.5h), low clearance (CL/F ss: 8.10-9.03L/h), long effective half-life (T ½,eff: ~12h, on average between 9.7 and 13.1h for 50, 200, and 600μgscqd), and large volume of distribution (V z/F ss: 251-1,091L) at steady state. Dose proportionality was confirmed for C max,ss; other PK parameters (C max, AUC0-24h and AUCtau) were approximately dose proportional. Growth hormone inhibition was observed with pasireotide 200 and 600μgscqd. Gallbladder volume increased post-prandially with pasireotide 200 and 600μgscqd, which appeared to correlate with reduced levels of cholecystokinin at these doses. Pasireotide was generally well tolerated up to the tested dose of 600μgqd, with a linear and time-independent PK profile after sc qd dosing in healthy subject
Regulation of Kainate Receptor Subunit mRNA by Stress and Corticosteroids in the Rat Hippocampus
Kainate receptors are a class of ionotropic glutamate receptors that have a role in the modulation of glutamate release and synaptic plasticity in the hippocampal formation. Previous studies have implicated corticosteroids in the regulation of these receptors and recent clinical work has shown that polymorphisms in kainate receptor subunit genes are associated with susceptibility to major depression and response to anti-depressant treatment. In the present study we sought to examine the effects of chronic stress and corticosteroid treatments upon the expression of the mRNA of kainate receptor subunits GluR5-7 and KA1-2. Our results show that, after 7 days, adrenalectomy results in increased expression of hippocampal KA1, GluR6 and GluR7 mRNAs, an effect which is reversed by treatment with corticosterone in the case of KA1 and GluR7 and by aldosterone treatment in the case of GluR6. 21 days of chronic restraint stress (CRS) elevated the expression of the KA1 subunit, but had no effect on the expression of the other subunits. Similarly, 21 days of treatment with a moderate dose of corticosterone also increased KA1 mRNA in the dentate gyrus, whereas a high corticosterone dose has no effect. Our results suggest an interaction between hippocampal kainate receptor composition and the hypothalamic-pituitary-adrenal (HPA) axis and show a selective chronic stress induced modulation of the KA1 subunit in the dentate gyrus and CA3 that has implications for stress-induced adaptive structural plasticity
Organic pollutants in sea-surface microlayer and aerosol in thecoastal environment of Leghorn—(Tyrrhenian Sea)
The levels of dissolved and particle-associated n-alkanes, alkylbenzenes, phthalates, PAHs, anionic surfactants and
surfactant fluorescent organic matter ŽSFOM. were measured in sea-surface microlayer ŽSML. and sub-surface water ŽSSL.
samples collected in the Leghorn marine environment in September and October 1999.
Nine stations, located in the Leghorn harbour and at increasing distances from the Port, were sampled three times on the
same day. At all the stations, SML concentrations of the selected organic compounds were significantly higher than SSL
values and the enrichment factors ŽEFsSML concentrationrSSL concentration. were greater in the particulate phase than
in the dissolved phase.
SML concentrations varied greatly among the sampling sites, the highest levels Žn-alkanes 3674 mgrl, phthalates 177
mgrl, total PAHs 226 mgrl. being found in the particulate phase in the Leghorn harbour.
To improve the knowledge on pollutant exchanges between sea-surface waters and atmosphere, the validity of spray drop
adsorption model ŽSDAM. was verified for SFOM, surface-active agents, such as phthalates, and compounds which can
interact with SFOM, such as n-alkanes and PAHs. q2001 Elsevier Science B.V. All rights reserved
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment
A control system analysis of the dynamic response of N-methyl-D-aspartate glutamate receptors to alcoholism and alcohol withdrawal
an analytical cross-sectional study
HINTERGRUND und ZIELSETZUNG: Die Hepatitis B und C gehören weltweit zu den
häufigsten Infektionskrankheiten. Sie sind wesentliche Risikofaktoren für die
Entwicklung einer Leberzirrhose bzw. eines hepatozellulären Karzinoms. Die
Prävalenz in Deutschland wird für beide Entitäten bei jeweils ca. 0,5%
angegeben bzw. geschätzt. Die frühe Erkennung und Therapie einer Hepatitis B
und C senkt als Maßnahme der Sekundärprävention die Mortalität. Deshalb wird
ein Screening, insbesondere von Risikogruppen, mittels serologischer Tests
empfohlen. Zielsetzung dieser Arbeit war zum einen die PrĂĽfung der
tatsächlichen Prävalenz von Hepatitis B und C bei Patienten einer Berliner
Rettungsstelle und zum anderen die Evaluation eines Fragebogens, der
spezifische Risikofaktoren abfragt. METHODIK: Bei Patienten der
interdisziplinären Rettungsstelle der Charité am Campus Benjamin Franklin
wurden nach Aufklärung und schriftlicher Zustimmung serologische Tests auf
Hepatitis B und C durchgefĂĽhrt (HBsAg, Anti-HBc, HCV-AK). Im Falle eines
reaktiven Anti-HBc Ergebnisses wurde Anti-HBsAg bestimmt. Ein reaktives HCV-
AK-Ergebnis galt erst nach einem positiven Bestätigungstest (Immunoblot) als
reaktiv. Personen mit reaktivem HBsAg- oder HCV-AK-Ergebnis wurden
nachverfolgt und weiter untersucht. Zusätzlich wurde ein von den
Studienteilnehmern ausgefĂĽllter standardisierter Fragebogen mit 14 Fragen zu
mit Hepatitis-assoziierten Faktoren ausgewertet. ERGEBNISSE: 1942 Personen
zwischen 18 und 97 Jahren nahmen an der Untersuchung teil. Nach
Alterskorrektur wurden folgende Seroprävalenzen festgestellt: HBsAg: 0,4% (95%
CI: 0,1-0,7%), Anti-HBc: 8,3% (95% CI: 7,1-9,5%), HCV-AK: 0,9% (95% CI:
0,5-1,3%). Bei allen 5 Personen mit reaktivem HBsAg-Befund, die nachverfolgt
werden konnten, lag eine chronische Hepatitis vor – bei 60% (3/5) bestand eine
sofortige Behandlungsindikation. Von den 17 Personen mit bestätigt reaktivem
HCV-AK-Ergebnis lag bei 55% (9/17) eine chronische Infektion vor. Bei 5 der 6
Personen mit aktuellem HCV-RNA-Nachweis in der PCR war die Infektion bereits
bekannt - eine Behandlungsindikation ergab sich in keinem Fall. Bei der
Auswertung des Fragebogens zeigte sich die Angabe der Herkunft aus
Hochprävalenzgebieten statistisch hochsignifikant mit einem reaktivem HBsAg-
Ergebnis assoziiert (OR 20,62; 95% CI: 4,14-102,80). BezĂĽglich des HCV-AK-
Status ergab sich eine statistisch signifikante Assoziation mit der Frage nach
parenteralen Risikofaktoren (OR: 3,65; 95% CI: 1,35-9,85) SCHLUSSFOLGERUNG:
Die hier erhobenen Prävalenzen von chronischer und durchgemachter Hepatitis B
und C decken sich mit den Daten größerer Bevölkerungsstichproben. Das
Vorliegen einer chronischen Hepatitis B war – anders als bei der chronischen
Hepatitis C - in den meisten Fällen bislang nicht bekannt. Eine Herkunft aus
Ländern mit erhöhter Prävalenz für HBV-Infektionen ist der stärkste
Risikofaktor fĂĽr das Vorliegen einer chronischen Hepatitis B.
Gesundheitspolitische Maßnahmen zur Prävention und Identifikation (Screening)
von Hepatitis B und deren Folgen sollten diese Bevölkerungsgruppe besonders
berĂĽcksichtigen. FĂĽr die HCV-Infektion wurden parenterale Risikofaktoren durch
den Fragebogen als wichtigster Risikofaktor im untersuchten Kollektiv
bestätigt. Die meisten Fälle mit HCV-Infektionen waren den Betroffenen
bekannt. Damit scheint das unbekannte Infektionsrisiko für die Bevölkerung
eher gering zu sein. Der hier eingesetzte Fragebogen zu Risikofaktoren einer
Virushepatitis ist als Vorselektionskriterium zur Detektion von chronischen
und somit behandlungsbedĂĽrftigen Virushepatitiden bei zu geringer
Spezifität/Trennschärfe der Fragen nicht geeignet.BACKGROUND and AIM of the study: Hepatitis B and C belong to the most common
infectious diseases in the world. They often result in cirrhosis of the liver
and hepatocellular carcinoma. The prevalence of both entities in Germany is
estimated to be around 0,5%. Early detection and treatment as a measure of
secondary prevention lowers mortality. Therefore screening by serological
testing, especially of risk groups, is recommended. In this work we
investigated the actual prevalence of Hepatitis B and C in an emergency
department in Berlin and evaluated a questionnaire focusing on specific risk
factors. METHODS: Patients attending the Charité Department of Emergency
Medicine at the Campus Benjamin Franklin in Berlin were tested for hepatitis B
and C after informed written consent (HBsAg, anti-HBc, HCV-antibodies). If the
anti-HBc-test was reactive, anti-HBsAg was tested. HCV-antibody tests had to
be confirmed by a positive control test (immunoblot). Those with reactive
HBsAg- or HCV-antibody-results were followed up and examined further. In
addition a standardized questionnaire containing 14 items which are connected
to viral hepatitis was answered by the participants and analyzed. RESULTS:
1942 peoples aged 18-97 years were tested. The following seroprevalences were
detected (after age-adjustment): HBsAg: 0,4% (95% CI: 0,1-0,7%), anti-HBc:
8,3% (95% CI: 7,1-9,5%), HCV-antibody: 0,9% (95% CI: 0,5-1,3%). All 5 persons
with reactive HBsAg-results who could be followed up had chronic hepatitis. In
60% (3/5) of the cases there was indication for immediate treatment. Out of 17
patients with confirmed reactive HCV-antibody-results 55% (9/17) had a chronic
infection. In 5 of 6 cases with current HCV-RNA-verification by PCR the
infection was already known - there was no indication for treatment. Analyzing
the questionnaire, origin from high-prevalence-countries was statistically
significantly associated with reactive HBsAg-results (OR 20,62; 95% CI:
4,14-102,80). As far as HCV-antibody results are concerned, parenteral risk
factors showed a statistically significant association (OR: 3,65; 95% CI:
1,35-9,85). CONCLUSIONS: The prevalence of chronic viral hepatitis or contact
with hepatitis B or C in the past matches the existing data from population-
based-surveys. Chronic hepatitis B was – in contrast to hepatitis C - unknown
in most of the cases. Migration background from high-prevalence-countries is
the most important risk factor for chronic hepatitis B in the studied
population. Public health measures in Germany for the prevention and screening
for hepatitis B should therefore especially include this part of the
population. For HCV-infection parenteral risk factors were confirmed being the
main risk for HCV-infection in the study population. According to the results
of this survey with mostly known HCV-infections the unknown risk of infection
for the general population seems to be rather low. The questionnaire used in
this survey about risk factors of viral hepatitis is not useful as
preselecting-criteria for detecting chronic viral hepatitis requiring
treatment because of insufficient specificity/discriminatory power
Pre-Award and Contract Services
Pre-Award and Contract Services assists campus faculty and staff in searching for funding sources, assistance in preparation of proposals, and submission of proposals to sponsors, including electronic transmissions via grants.gov and other electronic systems. Stop by and get information of finding funding sources through InfoEd\u27s SMARTS e-mail matching services, or the Community of Science PIVOT system. Check your faculty profile on Community of Science, or just stop by to chat about your interests
Evaluation of biomarkers for pharmacological activity
In recent years the cost of drug development has increased the demands on efficiency in the selection of suitable drug candidates. Biomarkers for efficacy and safety could be a plausible strategy to improve this selection process. In the present work, we focus on the study and evaluation of different physiological variables as biomarkers for pharmacological activity. We proposed three different approaches using multivariate and univariate techniques. We note that even though one could argue that the multivariate procedure is more powerful than the other alternatives, the univariate methods also offer a great flexibility to answer interesting scientific questions. The three approaches were used to analyze a crossover study involving an opioid antagonist.status: publishe
Chronic Hepatitis E With Genotype 1—Masquerading as Allograft Rejection After LiverTransplantation
- …